A microbiologist with interest in microbial physiology and metabolism. Current research focuses on the biology of pathogenic and non-pathogenic clostridia, in particluar in vivo metabolism and cell-to-cell communication. Also active in metabolic engineering, using both systems and synthetic biology approaches.
I am the foundation Professor of Systems Biology and Engineering within the Department of Chemical and Process Engineering (CPE), at The University of Sheffield. My research philosophy is centred on a mechanistic systems biology approach to solve biochemical reaction engineered processes. I wish to pursue issues involved in the effective utilisation of biological resources. The approach is specifically targeted at the conjunction of chemical engineering (metabolic engineering and synthetic biology),
I am an Assistant Professor at Leiden University in the Leiden Institute of Advanced Computer Science. I am a bioinformatician and my research interests are in data integration. I use scientific workflows and semantic web technologies to integrate and analyse data in systems biology and functional genomics.
University Education: 1987-1993, Biotechnology (Diploma), Technische Universität Braunschweig, Germany.
Dissertation: 1993-1996, Disseration German Research Centre for Biotechnology, Biochemical Engineering Division, Braunschweig, Germany.
Habiliation: 2006, Saarland University, Saarbrücken, Germany.
1993-1996: Research Assistant, German Research Centre for Biotechnology, Biochemical Engineering Division, Braunschweig, Germany.
1997-1998: Post-doc at Department of Applied Chemistry &
Prof. Dr. Volker F. Wendisch is Chair of Genetics of Prokaryotes at the Faculty of Biology at Bielefeld University. Since 2010 he is member of the board of Center for Biotechnology CeBiTec and since 2014 member of the senate of Bielefeld University. He studied biology in Köln University. After having completed his PhD at the Research Center Jülich in 1997, He worked as postdoctoral researcher at the University of California, Berkeley, CA, USA. From 2006-2009 he was Professor for Metabolic Engineering
Projects: de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik"https://orcid.org/0000-0002-9077-5664
Projects: de.NBI-SysBio, GenoSysFat, Kinetics on the move - Workshop 2016, Example use cases, COMBINE Multicellular Modelling, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik"https://orcid.org/0000-0002-5886-5563
I am a computer scientist by training with a specialisation on database and information systems. Since December 2018 I am professor of Medical Informatics at the University Medicine in Greifswald, Germany, at the Institute of Community Medicine. My lab focuses on research data management in biomedicine, data integration across health care providers, and provenance of clinical research data items within clinical information systems. Furthermore, I am actively involved in COMBINE standardisation
Lecturer/Assistant Prof in Computational Biology at the University of Ulster.
My research focusses principally on cholesterol metabolism and its role in cardiovascular disease and atherosclerosis. I have also studied its role in innate immunity and infection. In addition, I have worked on areas of personalised and stratified medicine for cardiovascular disease and rheumatoid arthritis.
My publications can be seen at: https://scholar.google.co.uk/citations?user=oMccxPwAAAAJ&hl=en
Anton JM Wagenmakers is Professor of Exercise Metabolism and Academic Lead of the Exercise Metabolism and Adaptation Research Group (EMARG) at Liverpool John Moores University, UK. Anton is a leading researcher in skeletal muscle and integrative human physiology and metabolism with 185 peer reviewed journal publications and a Web of Science h-index of 50. His research is focussing on mechanisms by which impairments in fat metabolism lead to impaired glucose tolerance, insulin resistance, and